MDP Share Price Performance
CA$2.65
0.50 (23.26%)
60.5% undervalued intrinsic discount
CA$6.71
Fair Value
Price CA$2.65
AnalystConsensusTarget CA$6.71
AnalystLowTarget CA$5.20
AnalystHighTarget CA$10.00
Fair ValueCA$6.71
Share Pricen/a
Medexus Pharmaceuticals Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
MDP Community Narratives
AN
Fair Value CA$6.71 60.5% undervalued intrinsic discount
US Transplant Centers Will Drive Specialty Care Adoption
1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value CA$5.55 52.3% undervalued intrinsic discount
Regulatory Pressure Will Limit Revenues While Allowing Cautious Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value CA$8 66.9% undervalued intrinsic discount
Aging Populations And Regulatory Tailwinds Will Expand Specialty Therapies
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Populations And Regulatory Tailwinds Will Expand Specialty Therapies
Key Takeaways Rapid adoption of GRAFAPEX and strong orphan drug positioning are set to elevate Medexus's gross margins and accelerate earnings growth across its portfolio. Medexus is poised for above-industry, long-term growth by leveraging demographic shifts, business development, and regulatory advantages supporting expansion in rare and chronic disease therapies.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CA$8
66.9% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
15.57% p.a.
Profit Margin
18.54%
Future PE
8.86x
Share price in 2028
CA$5.24
US Transplant Centers Will Drive Specialty Care Adoption
Key Takeaways Growth is driven by rapid adoption and high-margin performance of GRAFAPEX, supported by expansion in North American markets and increased therapy demand. Strategic acquisitions and portfolio diversification, alongside strengthening finances, position the company for sustainable long-term revenue and earnings growth.Read more
1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
CA$6.71
60.5% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
11.02% p.a.
Profit Margin
16.79%
Future PE
9.3x
Share price in 2028
CA$4.39
Regulatory Pressure Will Limit Revenues While Allowing Cautious Recovery
Key Takeaways Exposure to drug pricing pressure and regulatory scrutiny may limit revenue growth and increase operational challenges, especially as compliance costs rise. Heavy reliance on a few high-margin therapies creates vulnerability to market shifts, pricing changes, and evolving treatment paradigms.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CA$5.55
52.3% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
5.65% p.a.
Profit Margin
14.26%
Future PE
10.51x
Share price in 2028
CA$3.64
Recently Updated Narratives
AN
US Transplant Centers Will Drive Specialty Care Adoption
Fair Value: CA$6.71 60.5% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Pressure Will Limit Revenues While Allowing Cautious Recovery
Fair Value: CA$5.55 52.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations And Regulatory Tailwinds Will Expand Specialty Therapies
Fair Value: CA$8 66.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Medexus Pharmaceuticals Inc. Key Details
About MDP
- Founded
- 2018
- Employees
- 91
- CEO
- WebsiteView website
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2018 and is based in Toronto, Canada.
